Effects of bioavailable curcumin (Cureit®) supplementation in pre-sarcopenic and sarcopenic patients with gastrointestinal tract cancer

Not Applicable

Recruiting

• Conditions: Sarcopenia; C04.588.274.476

• Registration Number: RBR-8jmj76b
• Lead Sponsor: niversidade Federal de São Paulo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-05-25
• Last Update Posted: 29 May 2023
• Study Completion: 2023-12-10

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Volunteers diagnosed with some type of cancer in the gastrointestinal tract confirmed by biopsy or imaging; both genders; age over 18 years, Performance Status of Eastern Cooperative Oncology Group (ECOG) score less than or equal to 3; SARC-CalF greater than or equal to 11; decreased muscle mass; and/or decreased strength.

Exclusion Criteria

Volunteers using the chemotherapy drug Irinotecan; in dietary use of curcumin or supplements with curcuminoids or thermogenic; anticoagulants; presence of acute infection during the protocol; pregnant women; lactating women; cognitive limitations; physical limitations that prevent data collection; diagnosis of liver and kidney pathologies, gastric ulcer; participation in other clinical trials; use of Enteral or Parenteral Nutrition Therapy.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
It is expected to find an increase in strength of at least 20%, which will be evaluated by means of dynamometry, in the curcumin group, after 3 months of supplementation.

Secondary Outcome Measures

Name	Time	Method
An improvement in cell quality is expected, with an increase of 15% in the Phase Angle measurement, obtained through the evaluation of body composition by Tetrapolar Electrical Bioimpedance, in the turmeric group, after 3 months of supplementation.